Tackling the Taboo: A Sensible Prescription for Appropriate Cannabis use in Fibromyalgia

References

• Clauw DJ . Fibromyalgia: a clinical review. JAMA311(15), 1547–1555 (2014).
   PubMed Web of Science ®Google Scholar
• Rooks DS , GautamS , RomelingMet al. Group exercise, education, and combination self-management in women with fibromyalgia: a randomized trial. Arch. Intern. Med.167(20), 2192–2200 (2007).
   PubMedGoogle Scholar
• Goldenberg DL , BurckhardtC , CroffordL. Management of fibromyalgia syndrome. JAMA292(19), 2388–2395 (2004).
   PubMed Web of Science ®Google Scholar
• Bair MJ , MatthiasMS , NylandKAet al. Barriers and facilitators to chronic pain self-management: a qualitative study of primary care patients with comorbid musculoskeletal pain and depression. Pain Med.10(7), 1280–1290 (2009).
   PubMed Web of Science ®Google Scholar
• Boehnke KF . Pain management: assembling a tool kit, building a life. JAMA320(21), 2201–2202 (2018).
   PubMed Web of Science ®Google Scholar
• Whibley D , DeanLE , BasuN. Management of widespread pain and fibromyalgia. Curr. Treatm. Opt. Rheumatol.2(4), 312–320 (2016).
   PubMedGoogle Scholar
• Hauser W , JungE , Erbsloh-MollerBet al. The German fibromyalgia consumer reports - a cross-sectional survey. BMC Musculoskelet. Disord.13, 74 (2012).
   PubMed Web of Science ®Google Scholar
• Hauser W , PetzkeF , SommerC. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J. Pain11(6), 505–521 (2010).
   PubMed Web of Science ®Google Scholar
• Clauw DJ . Pain management: fibromyalgia drugs are ‘as good as it gets’ in chronic pain. Nat. Rev. Rheumatol.6(8), 439–440 (2010).
   PubMed Web of Science ®Google Scholar
• Hauser W , WalittB , FitzcharlesMA , SommerC. Review of pharmacological therapies in fibromyalgia syndrome. Arthritis Res. Ther.16(1), 201 (2014).
   PubMed Web of Science ®Google Scholar
• Boehnke KF , GagnierJJ , MatallanaL , WilliamsDA. Cannabidiol use for fibromyalgia: prevalence of use and perceptions of effectiveness in a large online survey. J. Pain22(5), 556–566 (2021).
   PubMedGoogle Scholar
• Boehnke KF , GagnierJJ , MatallanaL , WilliamsDA. Substituting cannabidiol for opioids and pain medications among individuals with fibromyalgia: a large online survey. J. Pain doi:10.1016/j.jpain.2021.04.011 (2021) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Boehnke KF , ScottJR , LitinasE , SisleyS , WilliamsDA , ClauwDJ. Pills to pot: observational analyses of cannabis substitution among medical cannabis users with chronic pain. J. Pain20(7), 830–841 (2019).
   PubMed Web of Science ®Google Scholar
• Boehnke KF , LitinasE , ClauwDJ. Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J. Pain17(6), 739–744 (2016).
   PubMed Web of Science ®Google Scholar
• Sagy I , Bar-LevSchleider L , Abu-ShakraM , NovackV. Safety and Efficacy of Medical Cannabis in Fibromyalgia. J. Clin. Med.8(6), 807 (2019).
   PubMed Web of Science ®Google Scholar
• Habib G , ArtulS. Medical Cannabis for the Treatment of Fibromyalgia. J. Clin. Rheumatol.24(5), 255–258 (2018).
   PubMedGoogle Scholar
• Fiz J , DuranM , CapellaD , CarbonellJ , FarreM. Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. PLoS ONE6(4), e18440 (2011).
   PubMed Web of Science ®Google Scholar
• Lucas P , WalshZ. Medical cannabis access, use, and substitution for prescription opioids and other substances: a survey of authorized medical cannabis patients. Int. J. Drug Policy42, 30–35 (2017).
   PubMed Web of Science ®Google Scholar
• Baron EP , LucasP , EadesJ , HogueO. Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. J. Headache Pain19(1), 37 (2018).
   PubMedGoogle Scholar
• Lucas P , BaronEP , JikomesN. Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients. Harm. Reduct. J.16(1), 9 (2019).
   PubMed Web of Science ®Google Scholar
• Lucas P , BoydS , MilloyMJ , WalshZ. Cannabis significantly reduces the use of prescription opioids and improves quality of life in authorized patients: results of a large prospective study. Pain Med. doi:10.1093/pm/pnaa396 (2020) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Lucas P . Rationale for cannabis-based interventions in the opioid overdose crisis. Harm. Reduct. J.14(1), 58 (2017).
   PubMedGoogle Scholar
• Mowry JB , SpykerDA , BrooksDE , McmillanN , SchaubenJL. 2014 annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 32nd annual report. Clin. Toxicol. (Phila.)53(10), 962–1147 (2015).
   PubMed Web of Science ®Google Scholar
• Fitzcharles MA , RampakakisE , SampalisJet al. Medical cannabis use by rheumatology patients following recreational legalization: a prospective observational study of 1000 patients in Canada. ACR Open Rheumatol. doi:10.1002/acr2.11138 (2020).
   PubMedGoogle Scholar
• Fisher E , MooreRA , FogartyAEet al. Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain doi:10.1097/j.pain.0000000000001929 (2020) ( Epub ahead of print).
   PubMedGoogle Scholar
• Marijuana Policy Project . Medical Marijuana patient numbers. http://www.mpp.org/issues/medical-marijuana/state-by-state-medical-marijuana-laws/medical-marijuana-patient-numbers/
   Google Scholar
• Boehnke KF , GangopadhyayS , ClauwDJ , HaffajeeRL. Qualifying conditions of medical cannabis license holders in the United States. Health Aff. (Millwood)38(2), 295–302 (2019).
   PubMed Web of Science ®Google Scholar
• Boehnke KF , ScottJR , LitinasEet al. Cannabis use preferences and decision-making among a cross-sectional cohort of medical cannabis patients with chronic pain. J. Pain20(11), 1362–1372 (2019).
   PubMed Web of Science ®Google Scholar
• Boehnke KF , GagnierJJ , MatallanaL , WilliamsDA. Cannabidiol product dosing and decision-making in a national survey of individuals with fibromyalgia. J. Pain doi:10.1016/j.jpain.2021.06.007 (2021) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Boehnke KF , LitinasE , WorthingB , ConineL , KrugerDJ. Communication between healthcare providers and medical cannabis patients regarding referral and medication substitution. J. Cannabis Res.3(1), 2 (2021).
   PubMedGoogle Scholar
• Durif-Bruckert C , RouxP , RoussetH. Medication and the patient-doctor relationship: a qualitative study with patients suffering from fibromyalgia. Health Expect18(6), 2584–2594 (2015).
   PubMed Web of Science ®Google Scholar
• Elwyn G , FroschD , ThomsonRet al. Shared decision making: a model for clinical practice. J. Gen. Intern. Med.27(10), 1361–1367 (2012).
   PubMed Web of Science ®Google Scholar
• Wood E , WerbD , MarshallBD , MontanerJS , KerrT. The war on drugs: a devastating public-policy disaster. Lancet373(9668), 989–990 (2009).
   PubMed Web of Science ®Google Scholar
• Devylder JE , MittalVA , SchiffmanJ. Balancing the public health costs of psychosis vs mass incarceration with the legalization of cannabis. JAMA Psychiatry78(3), 246–247 (2021).
   PubMed Web of Science ®Google Scholar
• Maccallum CA , EadieL , BarrAM , BoivinM , LuS. Practical strategies using medical cannabis to reduce harms associated with long term opioid use in chronic pain. Front. Pharmacol.12, 633168 (2021).
   PubMed Web of Science ®Google Scholar
• Heussler H , CohenJ , SiloveNet al. A Phase I/II, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome. J. Neurodev. Disord.11(1), 16 (2019).
   PubMedGoogle Scholar
• National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Population Health and Public Health Practice, Committee on the Health Effects of Marijuana . An evidence review and research agenda. In: The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research.National Academies Press, DC, USA (2017).
   Google Scholar
• Barry RA , GlantzSA. Marijuana Regulatory Frameworks in four US states: an analysis against a public health standard. Am. J. Public Health108(7), 914–923 (2018).
   PubMed Web of Science ®Google Scholar
• US FDA . FDA regulation of cannabis and cannabis-derived products, including cannabidiol (CBD). http://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd#farmbill
   Google Scholar
• Congressional Research Service . FDA regulation of cannabidiol (CBD) consumer products: overview and considerations for congress. http://www.everycrsreport.com/files/20200121_R46189_555bbafd9173e61dc0099f70a5ae2d71baea9f77.pdf
   Google Scholar
• Gurley BJ , MurphyTP , GulW , WalkerLA , ElsohlyM. Content versus label claims in cannabidiol (CBD)-containing products obtained from commercial outlets in the state of Mississippi. J. Diet17(Suppl. 5), 599–607 (2020).
   PubMed Web of Science ®Google Scholar
• Bonn-Miller MO , LoflinMJE , ThomasBF , MarcuJP , HykeT , VandreyR. Labeling accuracy of cannabidiol extracts sold online. JAMA318(17), 1708–1709 (2017).
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration . Warning letters and test results for cannabidiol-related products. http://www.fda.gov/news-events/public-health-focus/warning-letters-and-test-results-cannabidiol-related-products
   Google Scholar
• Ashton CH . Pharmacology and effects of cannabis: a brief review. Br. J. Psychiatry178, 101–106 (2001).
   PubMed Web of Science ®Google Scholar
• Freeman AM , PetrilliK , LeesRet al. How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. Neurosci. Biobehav. Rev.107, 696–712 (2019).
   PubMed Web of Science ®Google Scholar
• Silvestro S , MammanaS , CavalliE , BramantiP , MazzonE. Use of cannabidiol in the treatment of epilepsy: efficacy and security in clinical trials. Molecules24(8), 1459 (2019).
   PubMed Web of Science ®Google Scholar
• Masataka N . Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders. Front. Psychol.10, 2466 (2019).
   PubMedGoogle Scholar
• Nagarkatti P , PandeyR , RiederSA , HegdeVL , NagarkattiM. Cannabinoids as novel anti-inflammatory drugs. Future Med. Chem.1(7), 1333–1349 (2009).
   PubMed Web of Science ®Google Scholar
• Finn DP , HaroutounianS , HohmannAG , KraneE , SolimanN , RiceASC. Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies. Pain162(Suppl. 1), S5–S25 (2021).
   PubMedGoogle Scholar
• Mowry JB , SpykerDA , CantilenaLRJr , McmillanN , FordM. 2013 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 31st Annual Report. Clin. Toxicol. (Phila.)52(10), 1032–1283 (2014).
   PubMed Web of Science ®Google Scholar
• Boehnke KF , ClauwDJ. Brief commentary: cannabinoid dosing for chronic pain management. Ann. Intern. Med.170(2), 118 (2019).
   PubMed Web of Science ®Google Scholar
• Sihota A , SmithBK , AhmedSAet al. Consensus-based recommendations for titrating cannabinoids and tapering opioids for chronic pain control. Int. J. Clin. Pract.75(8), e13871 (2020).
   PubMed Web of Science ®Google Scholar
• Maccallum CA , RussoEB. Practical considerations in medical cannabis administration and dosing. Eur. J. Intern. Med.49(October 2017), 12–19 (2018).
   PubMedGoogle Scholar
• Bhaskar A , BellA , BoivinMet al. Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process. J. Cannabis Res.3(1), 22 (2021).
   PubMedGoogle Scholar
• Maccallum CA , RussoEB. Practical considerations in medical cannabis administration and dosing. Eur. J. Intern. Med.49, 12–19 (2018).
   PubMed Web of Science ®Google Scholar
• Sihota A , SmithBK , AhmedSAet al. Consensus-based recommendations for titrating cannabinoids and tapering opioids for chronic pain control. Int. J. Clin. Pract.75(8), e13871 (2021).
   PubMed Web of Science ®Google Scholar
• Wallace MS , MarcotteTD , AtkinsonJH , PadovanoHT , Bonn-MillerM. A Secondary analysis from a randomized trial on the effect of plasma tetrahydrocannabinol levels on pain reduction in painful diabetic peripheral neuropathy. J. Pain21(11–12), 1175–1186 (2020).
   PubMed Web of Science ®Google Scholar